AllergyTalk Episode 20: Methacholine Challenge Caveats, Biologic Super-Responders
Price: FREE for members and non-members
Speaker: Gerald Lee, MD
Viewers can earn credit by completing the post test questions
AllergyTalk is a podcast designed to provide easy access to research summaries from Allergy Watch and recommendations from subject matter experts in order to bring physicians up to date in the latest advances in the field of allergy and immunology.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this activity learners should be able to:
1. Discuss how omalizumab can modify the asthmatic response to rhinovirus infection.
2. Recognize situations when methacholine challenge may be false negative.
3. Identify characteristics that predict response to mepolizumab.
All identified conflicts of interest have been resolved.
Merin Kalangara (Kuruvilla), MD
Nothing to disclose
Gerald Lee, MD
Nothing to disclose
Stanley Fineman, MD
Disclosures: Speaker: AstraZeneca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance